| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in product development, particularly in the obesity treatment sector, with a focus on innovative drugs like retatrutide and orforglipron. The company has reported successful sales increases for its weight-loss drugs, highlighting strong market demand and effective product strategies. Additionally, investments in domestic manufacturing are enhancing production capabilities, ensuring a robust pipeline for future drug launches. Overall, the advancements in weight loss therapeutics underscore the company's commitment to addressing obesity and related health issues. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 2.1 is extremely bullish. The market sentiment at -0.2 is modestly bearish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.2, and the negative at -1.4 on 2026-02-04. The forces of Sentiment towards Fundamentals (3.2), Stock Price Trend (2.1), Sector Price Trend (1.2), Option Sentiment (0.8), and Valuation Sentiment (0.5) will drive up the price. The forces of Price Level Sentiment (-0.5), and Market Risk Appetite (-7.6) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | 2%(0.4%) | 1107.75 | 2.54% | 94 | 10.45% | 0.29% | 2.1 | 1.5 | 3.4% | -0.2 | Long | 60% | 3.2 | 6.2 |
| 2026-02-03 | 0%(0.1%) | 1002.98 | 2.57% | -2 | -3.85% | -0.37% | -1.3 | -1.2 | 1.9% | -0.5 | Wait | 50% | 2.8 | -1 |
| 2026-02-02 | 0%(0.1%) | 1043.09 | 2.21% | 33 | 0.49% | 0.04% | -0.6 | -0.1 | 0.9% | -0 | Short | 55% | 3.3 | -1 |
| 2026-02-01 | 0%(0.1%) | -0.6 | -0.1 | 0.1 | 3.4 | -1 | ||||||||
| 2026-01-31 | 0%(0.1%) | -0.6 | -0.1 | 0.1 | 3.3 | -1 | ||||||||
| 2026-01-30 | 1%(0.1%) | 1037.99 | 2.24% | 26 | 1.37% | 0.06% | -0.6 | 0.3 | 0.9% | 0.2 | Wait | 50% | 3.3 | 3.6 |
| 2026-01-29 | 0%(0%) | 1023.92 | 2.23% | 8 | 0.01% | -0.47% | -2 | -0.2 | 1.1% | 0.1 | Short | 55% | 3.4 | -1 |
| 2026-01-28 | 0%(0%) | 1023.79 | 2.09% | 2 | -1.46% | -0.5% | -1.8 | -0.2 | 2.1% | 0.4 | Short | 70% | 3.1 | 7 |
| 2026-01-27 | 0%(0%) | 1039.01 | 1.87% | 13 | -2.22% | -0.39% | -0.7 | -0.8 | 0.9% | 0.6 | Short | 55% | 2.7 | -1 |
| 2026-01-26 | 0%(0%) | 1062.65 | 1.73% | 41 | -0.15% | -0.01% | 0.4 | -0.2 | 1% | 0.5 | Short | 55% | 2.5 | -1 |
| Long is the preferred trading strategy with 60% chance of being right. Both trend sentiment and hourly trend are strong. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| 2026-02-04 22:48:08 Eli Lilly achieving a $1 trillion market valuation represents a significant milestone in the pharmaceutical industry, showcasing investor confidence. |
| 2026-02-04 22:48:08 The company's earnings report indicates strong revenue growth exceeding market expectations, reflecting a positive outlook for future profitability. |
| 2026-02-04 22:48:08 Eli Lilly has demonstrated robust stock performance, achieving a significant $1 trillion market cap and showing solid earnings that exceed expectations. |
| 2026-02-04 17:49:41 The company provided solid guidance following its earnings report, suggesting optimism for future performance. |
| 2026-02-04 17:49:41 Eli Lilly's market cap has reached over $1 trillion, indicating significant investor confidence. |
| 2026-02-04 17:49:41 Eli Lilly's earnings report exceeded expectations, highlighting the company's strong financial performance. |
| 2026-02-04 17:02:23 Despite strong performance, Eli Lilly faces challenges within a competitive landscape, particularly concerning its rivals and the need to maintain market leadership. |
| 2026-02-04 17:02:23 Eli Lilly is focused on future drug developments, including new weight loss products expected to launch soon, indicating strong ongoing innovation. |
| 2026-02-04 17:02:23 Eli Lilly's stock has seen significant increases following strong earnings reports and forecasts, reflecting overall positive investor sentiment and market confidence. |
| 2026-02-04 17:02:23 The articles emphasize Eli Lilly's impressive quarterly earnings, surpassing market expectations, and a positive outlook for 2026 driven by demand for its obesity and diabetes treatments. |
| 2026-02-04 17:02:23 Eli Lilly is emerging as a strong leader in the weight loss drug market, outperforming competitors like Novo Nordisk, showcasing its growing market share and innovative products. |
| 2026-02-04 15:48:30 Eli Lilly has crossed a $1 trillion market cap milestone, highlighting its strong market valuation. |
| 2026-02-04 15:48:30 Recent fluctuations in stock performance reflect the contrasting outlooks of Eli Lilly and Novo Nordisk in the market. |
| 2026-02-04 15:48:30 Eli Lilly's growth in the GLP-1 drug category demonstrates effective product development and a robust pipeline. |
| 2026-02-04 15:48:30 Eli Lilly has reported earnings that surpassed expectations, highlighting strong financial performance and growth prospects. |
| 2026-02-04 15:48:30 Novo Nordisk has issued a weak sales outlook for 2026, leading to a significant decline in its stock value. |
| 2026-02-04 15:48:30 Eli Lilly is increasingly positioned as a leader in the obesity drug market, significantly outperforming its main competitor, Novo Nordisk. |
| 2026-02-04 13:49:08 Eli Lilly is establishing a competitive advantage over rivals like Novo in the obesity drug market due to its successful product. |
| 2026-02-04 13:49:08 Eli Lilly is experiencing strong demand for its weight loss drug, which has positively impacted its sales forecast for the year. |
| 2026-02-04 11:48:39 Eli Lilly surpasses a $1 trillion market cap, reflecting positive market performance. |
| 2026-02-04 11:48:39 Eli Lilly's earnings exceeded expectations, showcasing robust financial health. |
| 2026-02-04 11:48:39 Eli Lilly's weight loss pill is on track for launch, indicating strong progress in product development. |
| 2026-02-04 09:35:08 Plans to establish new manufacturing facilities indicate Eli Lilly's commitment to scaling up production for future growth. |
| 2026-02-04 09:35:08 Eli Lilly's performance contrasts sharply with competitors, particularly Novo Nordisk, which is facing declining sales and profits. |
| 2026-02-04 09:35:08 Eli Lilly's stock has been performing well, partly due to better-than-expected earnings and positive guidance. |
| 2026-02-04 09:35:08 The substantial increase in sales of Mounjaro and Zepbound highlights the successful development and demand for Eli Lilly's weight-loss drugs. |
| 2026-02-04 09:35:08 Eli Lilly's strong quarterly earnings and positive growth outlook indicate robust financial performance and confidence in future sales. |